Teva Can Benefit by Acquiring Allergan Generics
The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.
Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success
On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.
Teva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.
Farallon Capital adds a new position in Covidien
Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.
What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?
Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.
Farallon Capital exits its position in Time Warner Cable
In February, Comcast agreed to buy Time Warner Cable for ~$45.2 billion. This deal will create the largest cable provider in the U.S.
Why Pershing Square initiated a position in Platform Specialty Products
Pershing Square disclosed a new position in Platform Specialty Products (PAH) that accounts for 7.58% of Pershing Square’s 1Q14 portfolio.
Key Risks Facing Sucampo Pharmaceuticals in 2017
Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.
Allergan–Pfizer merger: What Does Pfizer Make besides Viagra?
The Allergan–Pfizer merger will change Pfizer’s domicile to Dublin, Ireland, and allow them to gain access to overseas cash without a US repatriation tax.
This Space Presents a Market Opportunity for Valeant
In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.
Inside Alexion’s Metabolic Drugs Kanuma and Strensiq
In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.
Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings
Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.
What’s behind Biogen Buyout Rumors?
Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.
Why Ackman started a position in REIT Home Properties
Pershing Square disclosed a new position in Home Properties Inc. (HME) that accounts for 0.34% of Pershing Square’s $8.3 billion 1Q14 portfolio.
Why Did US Stock Indices Rise?
Treasury yields fell across the yield curve last week after the US Department of Labor reported that the economy added fewer jobs in April.
Must-know: Eton Park sells stake in Moody’s
Eton Park exited a position in Moody’s Corp (MCO) that accounted for 2.7% of the fund’s first quarter portfolio.
Entering Migraine Market Won’t Be Easy for Novartis, Amgen
Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.
Understanding Allergan’s Valuation after the 1Q17 Results
On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.
Point72 Reduces Its Stake in Valeant Pharmaceuticals
Point72 reduced its stake in Valeant Pharmaceuticals by selling 924,400 shares. It held 132,300 Valeant shares. Valeant accounted for 0.13% of the fund’s 4Q14 portfolio.
Farallon Capital raises its position in Safeway
On March 6, 2014, grocery store operators Safeway and Albertsons announced a merger agreement valued at approximately $9 billion.
What Might Have Fueled Valeant’s Interest in Salix?
The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
ITHAX’s Top Holding Was Trading above Moving Averages
Amazon was trading at 1.3%, 4.5%, and 33.1% above its 20-day, 50-day, and 200-day moving averages, respectively, as of December 28, 2015.
Eton Park opens new position in AerCap Holdings
Eton Park started a new position in AerCap Holdings (AER) that accounts for 1.39% of the fund’s second quarter portfolio.
Pfizer Has Received Commercial Rights for Cresemba in Europe
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
Why Eli Lilly Expects 2Q17 Revenue Growth
As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.
Farallon Capital establishes a new position in Hillshire Brands
Hillshire reported fiscal 4Q14 net sales of $1.1 billion, up 10.7% in comparison to the corresponding period last year.
What Are Analysts Estimating for Allergan Today?
AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).
Pershing Square takes on Zoetis, adds to Canadian Pacific in 3Q14
Activist hedge fund manager William Ackman’s Pershing Square Capital Holdings filed its third quarter 13F last month. The fund’s year-to-date returns as of October 31, 2014, net of fees, was 35.0%.
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Bill Gross: Top Stock Picks with High Dividend Yields
On October 18, CNBC reported Bill Gross top picks. His top stock picks were Annaly Capital (NLY), Invesco (IVZ) and Allergan (AGN).
Limited risk of Herbalife stock price increase, Ackman believes
Ackman believes there’s little chance of an Herbalife stock price increase and said Herbalife’s stock price is down almost 50%.
Carl Icahn Says Allergan Is Undervalued, Takes a Large Position
“Allergan has a great pipeline,” said Icahn. For Icahn, this healthcare sector (XLV) firm’s stock appears to be undervalued.
Wellington Management: Analyzing Its Top Holdings
Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.
AbbVie Announces Acquisition of Allergan: What You Should Know
On June 25, AbbVie (ABBV) announced a definitive agreement to acquire Allergan (AGN) in a cash and stock transaction for a total consideration of $63 billion. The deal values Allergan at a 45% premium to its closing price on June 24. AbbVie aims to reduce excessive revenue exposure to Humira through this deal.
What’s Pulling Down Allergan’s Share Price in 2019?
On March 6, Allergan (AGN) issued a press release announcing the failure of its investigational therapy rapastinel to meet the primary and secondary end points in three pivotal trials evaluating it as an adjunctive therapy in combination with antidepressant therapy in major depressive disorder indications.
How Is Allergan’s Revenue Trending in 2019?
In its first-quarter earnings investor presentation, Allergan (AGN) revised its 2019 revenue guidance upward from its previous estimate of $15.0 billion–$15.3 billion to $15.1 billion–$15.4 billion.
AbbVie or Allergan: Which Is a Better Pick in June?
AbbVie (ABBV) is down 14.69%, and Allergan (AGN) is down 13.41% in 2019 on a year-to-date basis. While concerns about the anticipated generic erosion of its flagship Humira franchise have proved to be a drag for AbbVie, Allergan is being increasingly criticized for a couple of reasons.
Where’s the ‘Next Warren Buffett’ Placing His Bets?
After Twenty-First Century Fox (FOX) (FOXA), Cheniere Energy (LNG) is Seth Klarman’s biggest bet.
Why Twenty-First Century Fox Remains Seth Klarman’s Favorite Bet
Seth Klarman’s portfolio value at the end of the fourth quarter was $11.5 billion.
What Analysts Are Recommending for Teva Pharmaceutical This Month
On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price.
A Financial Overview of Teva Pharmaceutical in December
In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.
Teva Pharmaceutical Stock Rose More than ~8% on December 26
On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.
Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.
A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.
How Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.
Recommendations for Shire as of October 30
Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.
Amgen: Expect Nearly Flat Revenues in Q3
New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.
How JNJ’s Invega Sustenna and Risperdal Consta Performed
Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter.
Allergan’s Q3 2018 Estimates: Revenue Decline Expected
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.
Allergan’s Q3 2018 Earnings: Analysts’ Estimates
Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
On October 2, Johnson & Johnson announced the completion of the divestiture of its LifeScan business to Platinum Equity for ~$2.1 billion.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
A Closer Look at the Allergan–Bonti Deal
On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.
Allergan’s Developments in September
On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.
What’s Eli Lilly’s Valuation as of September 27?
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
How Pharmaceutical ETFs Have Performed in 2018
The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).
These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
Pharmaceutical stocks that have surpassed the S&P 500 Index’s returns YTD include Eli Lilly, Pfizer, Merck, Allergan, and GlaxoSmithKline.
Allergan Unveils Spotlyte, Its First Digital Ventures Launch
On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit.
Allergan Launches the SkinMedica Lumivive System
On September 6, Allergan (AGN) announced the launch of its new innovative dual-acting product, the SkinMedica Lumivive System.
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.
Examining Amgen’s Revenue Trend in Q2 2018
Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.
FDA Approval Pushes Dermira’s Stock Price Up
Today, Dermira (DERM) announced FDA approval for its Qbrexza™ (glycopyrronium) cloth as a treatment option for primary axillary hyperhidrosis or excessive armpit sweating in both adults and pediatric patients above nine years of age.
Pfizer’s EC Approval of Xeljanz for Active Psoriatic Arthritis
Pfizer (PFE) announced in a press release yesterday that the European Commission has approved its marketing authorization application for Xeljanz in combination with methotrexate for active psoriatic arthritis.
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.
Viking Therapeutics Stock Rose 101% on May 31
On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.
No Bid Coming for Shire Reportedly
Will Allergan buy Shire? – Apparently not CNBC saying no bid is likely. Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier. From earlier: Shire PLC (NASDAQ: SHPG) is up 4.5% as of 11:10 A.M. on Thursday following an announcement […]
How Eli Lilly’s Endocrine Products Performed in 4Q17
Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment includes the endocrine products Humalog, Humulin, and Forteo.
How Novartis’s Ophthalmology Business Performed in 2017
In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.
Sanofi’s Valuations in February 2018
Sanofi (SNY) reported revenues of ~8.7 billion euros in 4Q17, a decline of ~2.0% in revenues compared to ~8.9 billion euros in 4Q16.
Comparing Eli Lilly’s Post-4Q17 Valuation
Eli Lilly’s valuation In 4Q17, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ EPS (earnings per share) and revenue estimates of $1.07 and ~$5.9 billion, respectively, reporting EPS of $1.14 on revenue of ~$6.2 billion. The above chart shows Eli Lilly’s EPS and revenue since 1Q16. In fiscal 2017, Eli Lilly reported EPS of $4.28 on […]
A Look at Eli Lilly’s Neuroscience Portfolio in 4Q17
Neuroscience portfolio Eli Lilly and Company’s (LLY) human pharmaceutical segment includes neuroscience products Cymbalta, Strattera, Prozac, and Zyprexa. Overall sales for neuroscience products fell in 4Q17 due to lower Strattera, Prozac, and Zyprexa sales, and were partially offset by strong Cymbalta sales. Cymbalta The above chart shows Eli Lilly’s neuroscience revenue since 1Q16. Cymbalta, an antidepressant drug, generated revenue […]
How Pfizer’s Peri-LOE Products Performed in 2017
Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.
Eli Lilly’s 4Q17 Estimates: Elanco
Elanco is expected to report growth in revenues during 4Q17, following strong sales and a favorable impact of foreign exchange.
Pfizer’s 4Q17 Estimates: Products with Lower Sales
In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.
What to Expect for Novartis’s Subsidiary Alcon in 2018
In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.4 billion, $1.5 billion, and $1.5 billion, respectively.
Merck & Co.’s Animal Health Business in 3Q17
Merck’s (MRK) Animal Health segment’s total revenues increased ~16% to $1 billion in 3Q17 compared to $865 million in 3Q16.
Johnson & Johnson’s Revenue Estimates for 4Q17
Johnson & Johnson’s (JNJ) Pharmaceutical segment contributes more than 45% to total revenues. In 4Q17, it’s expected to report growth in operating revenues.
Why Micron Technology Was Tepper’s Top Holding in 3Q17
Appaloosa Management was the ninth-largest investor in Micron Technology with 17 million shares as of September 30, 2017.
How Did Bausch + Lomb’s Top Products Perform in 3Q17?
In 3Q17, Valeant Pharmaceuticals’ Bausch + Lomb’s Soflens generated revenues of $83 million, which was ~5% higher on a YoY basis and ~9% higher QoQ.
Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape
In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.
Allergan on the Street: Analyst Recommendations This December
As of December 6, 2017, of the 24 analysts tracking Allergan stock, 17 recommend a “buy,” while seven recommend a “hold.” None recommends a “sell.”
How Pfizer’s Premarin and Other Legacy Established Products Performed
In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis.
Inside Novartis’s Ophthalmology Drugs Now
In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
Allergan’s 3Q17 Earnings: Analysts’ Estimates
Allergan (AGN) is one of the leading pharmaceutical companies, and it’s set to release its 3Q17 earnings on November 1.
Healthcare Was September Loser for US Domestic Moats
The healthcare sector has been the most challenged sector since the presidential elections in November 2016.
Merck’s 3Q17 Revenues Could Rise
Analysts expect Merck’s (MRK) revenues for 3Q17 to be around $10,546 million, nearly a 0.1% increase as compared to the revenues of $10,536 million reported for 3Q16.
Allergan Stock: Performance in 3Q17
Allergan stock has fallen ~15.4% in 3Q17. It has fallen 9.8% year-to-date as of October 20, 2017.
Vabomere: Major Addition to The Medicines Company’s Portfolio?
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
What Will Help Eli Lilly Build a Stronger Migraine Portfolio?
In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.
This Could Be Eli Lilly’s Long-Term Growth Driver
In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.
Quarterly Performance of Eli Lilly’s Neuroscience Products
Strattera, a drug for attention-deficit/hyperactivity disorder, reported a 17.0% fall in revenues to $186.6 million in 2Q17 compared to $224.6 million in 2Q16.